Have Questions? Call Us Toll Free (877) 880-5251

Lucentis gains FDA approval for treating diabetic retinopathy

Earlier this month, the FDA expanded the approved use of Lucentis to include its use in treating diabetic retinopathy in people who have diabetic macular edema. The announcement came after two clinical studies confirmed the drug's safety and efficacy in treating diabetic retinopathy in diabetic macular edema patients. Patients involved in the study who received Lucentis injections showed significant improvement in their condition when compared to those participants who did not receive Lucentis injections. Lucentis is also used to treat diabetic macular edema secondary to retinal vein occlusions and wet macular degeneration. Lucentis injections are administered into the eye on a monthly basis by a physician. Along with these injections, diabetic patients are also encouraged to control their blood sugar, blood pressure and cholesterol levels.*  

Search VisiVite